ReviewCardiac failure review2026
Non-positive Airway Pressure Therapies for Obstructive Sleep Apnoea and Central Sleep Apnoea.
Review in Cardiac failure review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obstructive sleep apnoea and central sleep apnoea are common disorders, particularly in people with congestive heart failure. Continuous positive airway pressure provides transformative benefits for some patients, but is not always well tolerated. Thus, considerable focus is now being placed on alternative therapies for sleep-disordered breathing, including non-positive airway pressure therapy. Advances in pharmacology have led to a variety of options to treat both obstructive and central sleep apnoea. In addition, these approaches may have major benefits from the perspective of preventing the complications of sleep-disordered breathing. In the case of tirzepatide, the Food and Drug Administration recently approved this medication for the treatment of moderate-to-severe sleep apnoea in people with obesity. However, further data are required regarding how best to improve both subjective and objective hard outcomes in people with congestive heart failure and sleep-disordered breathing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.